Chengda Biotech said at the 2026 semi-annual results briefing held on September 22 that the company's human diploid rabies vaccine now has large-scale production conditions, and the annual production capacity is expected to reach 10 million doses. On September 15, the first batch of the company's human diploid rabies vaccine was officially shipped and marketed from Chengda Biotech Benxi Company.

Chengda Biotech said at the 2026 semi-annual results briefing held on September 22 that the company's human diploid rabies vaccine now has large-scale production conditions, and the annual production capacity is expected to reach 10 million doses. On September 15, the first batch of the company's human diploid rabies vaccine was officially shipped and marketed from Chengda Biotech Benxi Company.